Abstracts Archive - Page 327 of 1683 - ATC Abstracts

2021 American Transplant Congress
Clazakizumab for the Treatment of Chronic Active Antibody-Mediated Rejection in Kidney Transplant Recipients: Phase 3 IMAGINE Study Design
P. Nickerson¹, G. Böhmig², S. Chadban³, D. Kumar⁴, R. B. Mannon⁵, T. van Gelder⁶, S. Adler⁷, E. Chong⁷, A. Djamali⁸
¹University of Manitoba, Winnipeg, MB, Canada, ²Medical University of Vienna, Vienna, Austria, ³University of Sydney, Sydney, Australia, ⁴University of Toronto, Toronto, ON, Canada, ⁵University of Nebraska Medical Center, Omaha, NE, ⁶Leiden University Medical Center, Leiden, Netherlands, ⁷CSL Behring, King of Prussia, PA, ⁸University of Wisconsin, Madison, WI
*Purpose: Chronic active antibody-mediated rejection (CAMR) is a major cause of allograft loss with no approved drugs for its treatment. Currently, off-label regimens recommended by…
2021 American Transplant Congress
Kidney Transplant Recipients Who Had Covid-19 Prior to Transplant: A Single-center Experience
S. Sultan, M. Aull, R. Craig-Schapiro, E. C. Liu, J. H. Lee, S. Kapur
New York Presbyterian / Weill Cornell, New York, NY
*Purpose: In the early recovery phase after the initial surge of the COVID-19 pandemic, a question emerged in the context of resuming transplant activity: should…
2021 American Transplant Congress
Delayed Graft Function in Pediatric Living Donor Kidney Transplantation
M. MacConmara, J. Shah, L. de Gregorio, D. Desai, P. Vagefi, C. S. Hwang
Surgery, UT Southwestern Medical Center, Dallas, TX
*Purpose: Pediatric recipients of living donor kidneys have a low rate of delayed graft function (DGF). The aim of this study was to examine the…
2021 American Transplant Congress
Hla Antigens and Recurrence of Focal Segmental Glomerulosclerosis in Pediatric Kidney Transplantation
B. I. Shaw¹, A. Ochoa², C. Chan², R. A. Gbadegesin³, A. M. Jackson¹, E. T. Chambers³
¹Surgery, Duke University, Durham, NC, ²Biostatistics and Bioinformatics, Duke University, Durham, NC, ³Pediatrics, Duke University, Durham, NC
*Purpose: Recurrence of focal segmental glomerulosclerosis (FSGS) reduces graft survival yet risk factors remain elusive. While HLA risk alleles are known to be associated with…
2021 American Transplant Congress
Role of Baseline PD-1 Checkpoint Inhibitor Pathway Expression in Bridge to Liver Transplant Hepatocellular Carcinoma
K. Nunez, T. Sandow, M. Hibino, A. Cohen, P. Thevenot
Ochsner Health, New Orleans, LA
*Purpose: Response to first line liver-directed therapy (LDT) in hepatocellular carcinoma (HCC) has important implications in both bridge to transplant (BTT) success as well as…
2021 American Transplant Congress
Outcomes of Downstaging Hepatocellular Carcinoma (HCC) to within Milan Criteria Before Liver Transplantation (LT): A Multicenter Analysis of the “All-comers” Protocol
B. Natarajan¹, P. Tabrizian², M. Hoteit³, C. Frenette⁴, T. Ghaziani⁵, R. Dhanasekaran⁵, N. Parikh⁶, J. Guy⁷, A. Shui¹, S. Florman², F. Yao¹, N. Mehta¹
¹UCSF, SF, CA, ²Mt Sinai, NY, NY, ³U Penn, Philadelphia, PA, ⁴Scripps, La Jolla, CA, ⁵Stanford, Palo Alto, CA, ⁶U Michigan, Ann Arbor, MI, ⁷CPMC, SF, CA
*Purpose: Patients with HCC meeting UNOS-downstaging (DS) criteria (1 lesion 5.1-8 cm, 2-3 lesions at least one 3.1-5 cm and total tumor diameter (TTD) ≤8…
2021 American Transplant Congress
Molecular Classifiers for Chronic Lung Allograft Dysfunction Transbronchial and Mucosal Biopsies Predict Clinical CLAD and Graft Loss
M. D. Parkes¹, P. F. Halloran², K. M. Halloran³, &. the INTERLUNG Study Group⁴
¹Alberta Transplant Applied Genomics Centre, Edmonton AB, AB, Canada, ²Alberta Transplant Applied Genomics Centre, Edmonton, AB, Canada, ³University of Alberta, Edmonton AB, AB, Canada, ⁴., ., AB, Canada
*Purpose: Chronic lung allograft dysfunction (CLAD) portends poor outcomes yet is poorly understood. In the multi-center INTERLUNG study we measured transcripts in transbronchial biopsies (TBBs)…
2021 American Transplant Congress
Racial and Ethnic Disparities in Pediatric Kidney Transplantation – Has KAS Made a Difference?
O. Charnaya¹, S. Yu², A. Goldberg³, J. Garonzik-Wang², D. Segev², P. Verghese⁴
¹Pediatrics, Johns Hopkins University, Baltimore, MD, ²Transplant Surgery, Johns Hopkins University, Baltimore, MD, ³University of Manitoba, Winninpeg, MB, Canada, ⁴Northwestern University Feinberg School of Medicine, Chicago, IL
*Purpose: Racial and ethnic minority pediatric transplant candidates have known disparities in access to kidney transplantation. The Kidney Allocation System (KAS), implemented in 2014, was…
2021 American Transplant Congress
Perioperative Blood Transfusion is Associated with the Development of New HLA Antibodies After Adult Lung Transplantation
A. Hicks¹, A. Stoker², M. Cooter², A. Ali³, J. Klapper⁴, J. Poisson⁵, D. Chen⁵, J. Haney⁴, K. Ghadimi², M. Hartwig⁴, I. Welsby², B. Bottiger²
¹Anesthesiology, Duke University Hospital, South Portland, ME, ²Anesthesiology, Duke University Hospital, Durham, NC, ³Pulmonology, Allergy and Critical Care Medicine, Duke University Hospital, Durham, NC, ⁴Cardiothoracic Surgery, Duke University Hospital, Durham, NC, ⁵Pathology, Duke University Hospital, Durham, NC
*Purpose: Lung transplant (LT) recipients who develop new antibodies to human leukocyte antigen (HLA) have associated with chronic lung allograft dysfunction and worsened outcomes. We…
2021 American Transplant Congress
Liver Transplantation for Unresectable Colorectal Cancer Liver Metastases: A Multicenter Experience
L. I. Ruffolo¹, K. Sasaki², K. Tomiyama¹, A. Nair¹, M. Orloff¹, B. Al-Judaibi³, M. Levstik³, M. Laryea³, K. Dokus¹, J. Errigo¹, A. Moro², C. Quintini², K. Hashimoto², M. Fujiki², K. Menon², C. Kwon², T. Diago Uso², R. Hernandez-Alejandro¹, F. Aucejo²
¹Surgery, University of Rochester Medical Center, Rochester, NY, ²Surgery, The Cleveland Clinic Foundation, Cleveland, OH, ³Transplant Hepatology, University of Rochester Medical Center, Rochester, NY
*Purpose: Colorectal cancer is the third leading cause of cancer related death, unfortunately 50% of patients will develop colorectal liver metastases (CRLM), and a minority…